Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis

Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E. Cortes

Research output: Contribution to journalLetter

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)e324-e327
JournalHaematologica
Volume101
Issue number8
DOIs
StatePublished - Jul 31 2016
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • High-dose imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology

Cite this

Sasaki, K., Kantarjian, H., Jabbour, E., Ravandi, F., Takahashi, K., Konopleva, M., Borthakur, G., Garcia-Manero, G., Wierda, W., Daver, N., Jain, P., Satta, T., Pierce, S., Rios, M. B., & Cortes, J. E. (2016). Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica, 101(8), e324-e327. https://doi.org/10.3324/haematol.2015.139089